Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs Gilead Sciences, Inc. (GILD) Price & Performance

Global X Robotics and Artificial Intelligence ETFTrade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

Global X Robotics and Artificial Intelligence ETF vs Gilead Sciences, Inc. — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $37.87, while Gilead Sciences, Inc. trades at $135.44 (market cap $168.35B). The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Global X Robotics and Artificial Intelligence ETF pays none. Which is the better fit depends on your goals.

BOTZGILD
52-Week High
$41.63$155.80
52-Week Low
$31.99$110.56
Market Cap
$168.35B
Sector
Health
Enterprise Value
$191.42B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Robotics and Artificial Intelligence ETF

BOTZ trades at $37.92, up 1.34% with a bullish technical signal supported by moving averages. The robotics and AI ETF shows strong momentum with key resistance at $38. Recent articles highlight BOTZ as the largest pure-play robotics fund, positioned to benefit from the shift from digital to physical AI applications. The fund offers exposure to global robotics leaders with a lower expense ratio than peers.

Outlook remains positive as robotics adoption accelerates globally, though overbought RSI signals near-term caution. Investment opportunity lies in AI's expansion into physical automation, while risks include sector concentration and valuation pressures in tech. The fund's global diversification provides exposure to non-US AI innovation.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.

The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Robotics and Artificial Intelligence ETF

The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.

Read more on BOTZ

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD